双重MdmX/Mdm2阻害剤によるがん細胞におけるp53の効率的な再活性化

Lingyun Qin¹, Fei Yang, Cindy Zhou

¹Department of Biotechnology and Collaborative Innovation Center for Industrial Fermentation, Hubei University of Technology , Wuhan 430068, China.

Journal of the American Chemical Society

|December 3, 2014

まとめ

新しい二重小分子薬は,がん細胞のMdm2/MdmXを標的としてp53経路を効果的に再活性化します. このアプローチは,これらのタンパク質を過剰に発現させるがんに対する有望な治療戦略を提供します.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
ドラッグ・ディスカバリー・ディスカバリー・ドラッグ・ディスカバリー・ドラッグ・ディスカバリー

背景:

異常なp53-Mdm2/MdmX相互作用は,ヒトがんの約50%でp53機能を損なう.
Mdm2および/またはMdmXの過剰発現は,がんにおけるp53不活性化の一般的なメカニズムである.
Mdm2とMdmXの両方の抑制は,単一標的抑制よりも,癌細胞アポトシスを促進する上でより大きな有効性を示しています.

研究の目的:

Mdm2とMdmXの両方を標的にする二重小分子アンタゴニストの開発と検証.
癌モデルにおけるp53経路の再活性化におけるこの二重抗体の有効性を評価する.
Mdm2/MdmX過剰発現のがんに対する潜在的な治療候補を確立する.

主な方法:

MdmX.のセグメンタル変異分析に基づく合理的な薬物設計.
ニュートリン-3aで複合されたMdm2 N端領域の結晶構造を用いて.
MdmXおよび/またはMdm2.2を過剰に発現するがん細胞モデルでダブルアンタゴニストの試験

主要な成果:

二重小分子対抗剤は,p53経路を効率的に再活性化しました.
MdmXおよび/またはMdm2.2を過剰発現するモデル癌細胞における有効性が実証されています.
実行可能な小分子治療候補を確立しました.

結論:

Mdm2とMdmXの二重抑制は,がん治療の強力な戦略です.
開発されたダブルアンタゴニストは,Mdm2/MdmX過剰発現がんに対する有望な治療候補である.
この研究は,腫瘍学におけるp53-Mdm2/MdmX軸をターゲットにする新しいアプローチを検証しています.

さらに関連する動画

05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.2K

10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.9K

関連する概念動画

02:23

Abnormal Proliferation

5.5K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

5.5K

02:36

DNA Damage can Stall the Cell Cycle

10.4K

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

10.4K

02:36

DNA Damage Can Stall the Cell Cycle

3.4K

01:23

Negative Regulator Molecules

39.2K

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

39.2K

02:34

Inhibition of Cdk Activity

6.3K

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

6.3K

01:31

The Intrinsic Apoptotic Pathway

9.4K

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...